Adrabetadex (DrugBank: Adrabetadex)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 19 | Lysosomal storage disease | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT03643562 (ClinicalTrials.gov) | June 18, 2018 | 19/8/2018 | Adrabetadex for Patients With Nerve Symptoms of Niemann-Pick Type C Disease (NPC) | Open-label Evaluation of Adrabetadex in Patients With Neurologic Manifestations of Niemann-Pick Type C Disease (NPC) | Niemann-Pick Type C Disease | Drug: Adrabetadex | Vtesse, Inc., a Mallinckrodt Pharmaceuticals Company | NULL | Active, not recruiting | 4 Years | N/A | All | 60 | Phase 3 | United States |